13073_2016_366_MOESM1_ESM.pdf (7.08 MB)
Additional file 1: Figure S1. of A case study of an integrative genomic and experimental therapeutic approach for rare tumors: identification of vulnerabilities in a pediatric poorly differentiated carcinoma
journal contribution
posted on 2016-10-31, 05:00 authored by Filemon Dela Cruz, Daniel Diolaiti, Andrew Turk, Allison Rainey, Alberto Ambesi-Impiombato, Stuart Andrews, Mahesh Mansukhani, Peter Nagy, Mariano Alvarez, Andrea Califano, Farhad Forouhar, Beata Modzelewski, Chelsey Mitchell, Darrell Yamashiro, Lianna Marks, Julia Glade Bender, Andrew KungActivation of mTOR pathway in patient tumor sample. Figure S2 A. Levels of in vitro translated MAX, MAXR60Q, C-MYC, and MXD1 in samples used for EMSA. B Modeling BRAF kinase domain complexed with ATP and Mg2+. Figure S3. Validation of PDX tumor model by Sanger sequencing. Figure S4. Tumor response to selumetinib. (PDF 7254Â kb)